Introduction:
Radium-223 has been recommended for patients with bone-dominant metastatic prostate cancer. The addition of second-generation hormone therapy (2nd HT) to radium-223 with mCRPC has been attempted, but its benefit has not yet been elucidated. Herein, we aim to investigate the potential benefit of the concomitant use of 2nd HT with radium-223 in the third-line setting.
Methods:
In a single-institution retrospective study, we identified 57 patients with bone-dominant mCRPC that were treated with radium-223 as a third-line therapy, either alone or with concomitant 2nd HT. Survival outcomes were assessed based on 3-year overall survival (OS).
Results:
Mean (±SD) age was 70.1 (±8.2) yrs., median (IQR) primary Gleason Score was 9 (7-9), median (IQR) pre-radium-223 ALK-P was 91 (67-117) and median (IQR) pre-radium-223 PSA was 21.1 (7.6-65.5) ng/ml. Median (IQR) number of Radium-223 cycles was 6 (5-6). 32 patients received radium-223 alone, and 25 patients received radium-223 with concomitant 2nd HT (n = 17 enzalutamide, n = 8 abiraterone). 3-year OS for radium-223 alone was 10% versus 25% and 10% with concomitant abiraterone or enzalutamide, respectively. There was no significant difference in 3-year OS between patients that received radium-223 alone versus those that received concomitant 2nd HT (Figure 1).
Conclusion:
Adding 2nd HT to radium-223 in the third-line setting did not provide any survival benefit in our retrospective study. Further prospective studies are warranted.
Funding: NA
Image(s) (click to enlarge):
Concomitant second-generation hormone therapy with Radium-223 in the third-line setting: Does it improve overall survival?
Category
Prostate Cancer > CRPC
Description
Poster #24
Wednesday, November 29
4:00 p.m. - 5:00 p.m.
Presented By: Kelly Lehner
Authors:
Kelly Lehner
Mohamed Ahmed
Ayse Tuba Kendi
Jack Andrews
Eugene Kwon